Phase II clinical study of eribulin monotherapy in Japanese patients with metastatic breast cancer who had well-defined taxane resistance
Eribulin
Taxane
Tolerability
Clinical endpoint
DOI:
10.1007/s10549-016-3808-x
Publication Date:
2016-04-28T17:21:46Z
AUTHORS (10)
ABSTRACT
No clinical evidence on the efficacy and safety of eribulin monotherapy has been obtained by a prospective study in patients with metastatic breast cancer (MBC) who had well-defined taxane resistance. The present Phase II, multicenter, single-arm, open-label aimed to obtain evidence. Japanese female patients, aged 33–74 years metastasis taxane-resistant histopathologically confirmed cancer, received mesylate 1.4 mg/m2 (equivalent 1.23 [expressed as free base]) 2- 5-min intravenous infusion days 1 8 each 21-day cycle. primary endpoint was benefit rate (CBR) [complete response (CR), partial (PR), long-term stable disease (LSD) ≥24 weeks]. A total 51 underwent chemotherapy cycles (median 4; range 1–42 cycles). CBR 39.2 % (CR 2.0 %; PR 23.5 LSD 13.7 %), progressive 49.0 %. median progression-free survival overall were 3.6 months [95 confidence interval (CI) 2.6–4.6 months] 11.7 (95 CI 9.2–14.2 months), respectively. Grade 3 or greater adverse events leukopenia (23.5 neutropenia (35.3 anemia (5.9 febrile (7.8 %). incidences grade 4 peripheral sensory neuropathy 0 %, Eribulin showed clinically manageable tolerability profile dose adjustments symptomatic treatment. effective well tolerated heavily pretreated MBC resistance, thus providing potential therapeutic option settings.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (28)
CITATIONS (31)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....